• Home
  • NEW DAY MEDICINE
  • 3 (89) 2026
  • 37 -3 (89) 2026 - Y.Sh. Khakimov, A.A. Yusupbekov, G.N. - COMPARATIVE ANALYSIS OF LONG-TERM OUTCOMES OF SURGICAL AND COMBINED TREATMENT FOR CARDIOESOPHAGEAL CANCER

37 -3 (89) 2026 - Y.Sh. Khakimov, A.A. Yusupbekov, G.N. - COMPARATIVE ANALYSIS OF LONG-TERM OUTCOMES OF SURGICAL AND COMBINED TREATMENT FOR CARDIOESOPHAGEAL CANCER

COMPARATIVE ANALYSIS OF LONG-TERM OUTCOMES OF SURGICAL AND COMBINED TREATMENT FOR CARDIOESOPHAGEAL CANCER

Y.Sh. Khakimov - Bukhara State Medical Institute named after Abu Ali ibn Sina

A.A. Yusupbekov - Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology Bukhara Branch Uzbekistan

G.N. Saidov - Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology Bukhara Branch Uzbekistan

E.E. Juraev - Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology Bukhara Branch Uzbekistan

B.B. Usmonov - Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology Bukhara Branch Uzbekistan

O.D. Tuychiev - Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology Bukhara Branch Uzbekistan

Resume

Cardioesophageal cancer (CEC) is one of the most aggressive malignancies of the gastroesophageal junction, characterized by early metastasis and poor prognosis. The aim of this study was to evaluate and compare the long-term outcomes of surgical and combined treatment approaches in patients with CEC. A total of 237 patients underwent radical surgical treatment, and long-term outcomes were assessed in 203 (85.6%) of them. Treatment effectiveness was evaluated based on quality of life using the Karnofsky scale, overall survival, recurrence-free survival, and metastasis-free survival. The results demonstrated that combined therapy (surgery combined with neoadjuvant and adjuvant chemotherapy) significantly improved the 5-year overall survival rate from 37.9% to 53.4%. Additionally, tumor histological type and degree of differentiation were identified as important prognostic factors influencing treatment outcomes.

Keywords: cardioesophageal cancer, surgical treatment, combined therapy, quality of life, survival, recurrence, metastasis.

First page

227

Last page

238

For citation:Y.Sh. Khakimov, A.A. Yusupbekov, G.N. Saidov, E.E. Juraev, B.B. Usmonov, O.D. Tuychiev - COMPARATIVE ANALYSIS OF LONG-TERM OUTCOMES OF SURGICAL AND COMBINED TREATMENT FOR CARDIOESOPHAGEAL CANCER//New Day in Medicine 3(89)2026 227-238 https://newdayworldmedicine.com/en/new_day_medicine/3-89-2026

List of References

  1. Ajani JA, D’Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(10):1286–1312. doi:10.6004/jnccn.2016.0137.
  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.
  3. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20. doi:10.1056/NEJMoa055531.
  4. Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 2017;390(10110):2383–2396. doi:10.1016/S0140-6736(17)31462-9.
  5. Lordick F, Shitara K, Janjigian YY. New agents on the horizon in gastric cancer. Nat Rev Clin Oncol. 2022;19(4):231–245. doi:10.1038/s41571-021-00574-4.
  6. Markar SR, Karthikesalingam A, Thrumurthy S, Low DE. Volume–outcome relationship in surgery for esophageal malignancy. Ann Surg. 2019;269(2):291–298. doi:10.1097/SLA.0000000000002491.
  7. Rice TW, Ishwaran H, Hofstetter WL, Schipper PH, Kesler KA, Law S, et al. Esophageal cancer: associations with (pN+) lymph node metastases. J Thorac Oncol. 2017;12(1):36–42. doi:10.1016/j.jtho.2016.09.125.
  8. Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS trial). Lancet Oncol. 2015;16(9):1090–1098. doi:10.1016/S1470-2045(15)00040-6.
  9. Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT, Lordick F. Gastric cancer. Lancet. 2017;390(10110):635–649. doi:10.1016/S0140-6736(17)31463-1.
  10. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660.
  11. van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–2084. doi:10.1056/NEJMoa1112088.

    file

    download